Business
Endonovo Establishing Its Footprint in Non-Invasive Bioelectronic Medicine Space -- SECFilings.com
Endonovo Establishing Its Footprint in Non-Invasive Bioelectronic Medicine Space -- SECFilings.com.
About this update from Endonovo Therapeutics, Inc.
[{"type":"text","content":"\n \n \n Endonovo Establishing Its Footprint in Non-Invasive Bioelectronic Medicine Space -- SECFilings.com\n \n \nEndonovo Establishing Its Footprint in Non-Invasive Bioelectronic Medicine Space -- SECFilings.com\n \n REDONDO BEACH, CA--(Marketwired - Sep 15, 2016) - SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces an article covering Endonovo Therapeutics' (OTCQB: ENDV) novel, non-invasive and NASA-developed bioelectronics technology. Also included is an executive interview with Endonovo CEO Alan Collier.\n The concept of electroceuticals, often called bioelectronics, dates back nearly three centuries to Italian physician, physicist and biologist Luigi Aloisio Galvani. Even though we see applications today, including the basic example of pacemakers, the scientific community is only beginning to scratch the surface of the opportunity at hand to modulate the body's neural superhighway to treat and prevent diseases and conditions.\n In naming their new joint venture company Galvani Bioelectronics, GlaxoSmithKline and Google parent Alphabet's life sciences unit paid tribute to the man widely credited for discovering animal electricity and pioneering bioelectromagnetics. In the world's most ambitious efforts in the electroceutical space to date, the two companies have agreed to spend $715 million across seven years to develop tiny, implantable devices aimed at modifying electrical nerve signals. The investment speaks volumes to the potential therapeutic benefits of bioelectronic devices.\n While several companies are addressing implantable devices, Endonovo Therapeutics is taking a different route in the electroceutical space. The company is focused on non-invasive devices for multiple applications, namely to prevent vital organs from failing by controlling inflammation through its Immunotronics technology and growing more potent stem cells with its Cytotronics platform.\n To read the article and see the interview, please click here: http://analysis.secfilings.com/articles/65-endonovo-establishing-its-footprint-in-non-invasive-bioelectronic-medicine-space\n To watch the interview alone on YouTube, use this link: https://youtu.be/mQMRAKWXTsw\n About SECFilings.com\n Founded in 2004, SECFilings.com provides free real time filing alerts to over 600,000 regi...